Monday, October 21, 2013
Hemera Bioscience Inc. is designing its MAC-based gene therapy to help treat
dry and wet age-related macular degeneration more safely than other therapies
targeting the complement pathway in ocular diseases. It also may offer more
convenient dosing and treat a wider variety of AMD types than marketed
injectable VEGF inhibitors.
Both the wet and dry forms of
AMD are characterized by over-activation of the complement cascade. While the
cascade plays a key role in maintaining the homeostasis of eye supporting
tissue and in helping the innate immune system respond to infection,
over-activation of the cascade in the retina is associated with chronic
pro-inflammatory damage that can lead to blindness.